Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994380 · ClinicalTrials.gov registry record · Phase 1
Use of DNAse in Neutrophilic Asthma
A Phase 1 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03994380: Completed Phase 1 study, sponsored by National Jewish Health.
NCT03994380 is a Phase 1 study that has completed, run by National Jewish Health. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994380, a Phase 1 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
In this pilot protocol, the researchers look to determine benefits from use of nebulized rh-DNase for 4 weeks in patients with neutrophilic asthma.
Primary Outcome
FEV1
Interventions
- DRUG RhDNAse Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
What the finished NCT03994380 record still lists
NCT03994380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which RhDNAse Inhalation Solution is the first listed.
NCT03994380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03994380 about?
NCT03994380 is a clinical study titled "Use of DNAse in Neutrophilic Asthma". In this pilot protocol, the researchers look to determine benefits from use of nebulized rh-DNase for 4 weeks in patients with neutrophilic asthma.
What is the current status of trial NCT03994380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-02-12. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03994380?
The interventions under investigation include: RhDNAse Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT03994380?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03994380's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI